Latest News

(UroToday.com) Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, the benefit of docetaxel in […]

(UroToday.com) One of the fastest moving disease spaces in prostate cancer in metastatic castration sensitive prostate cancer. While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options that have been shown to improve overall survival, including docetaxel and novel hormonal therapies including abiraterone acetate, enzalutamide, […]

(UroToday.com)  There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis, recently, theranostic treatment with 177Lu-PNT2002 (also known as [Lu-177]-PSMA-I&T) has demonstrated promising activity among pre-treated individuals with […]

Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and associate professor of medicine at Northwestern University in Chicago in the US. I’m so excited to have here with me today, a good friend and colleague, Dr. Stephen Freedland, who is a professor of urology and the director of the […]

(UroToday.com) Avelumab first-line maintenance is approved in various countries for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy based on significantly prolonged overall survival (OS) seen with avelumab + best supportive care versus best supportive care alone in the phase 3 JAVELIN Bladder 100 trial (HR 0.69, 95% CI 0.56 to […]

(UroToday.com) One of the fastest moving disease spaces in prostate cancer in metastatic castration-sensitive prostate cancer. While androgen-deprivation therapy (ADT) alone was the standard treatment five years ago, now there are a number of treatment options that have been shown to improve overall survival, including docetaxel, abiraterone acetate, enzalutamide, and apalutamide. The phase III ARCHES trial, […]

(UroToday.com) In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line maintenance + best supportive care significantly prolonged overall survival versus best supportive care alone in patients with advanced urothelial carcinoma that had not progressed on first-line platinum-based chemotherapy (HR 0.69, 95% CI 0.56 to 0.86; 1-sided p = 0.0005).1 Based on these results, avelumab first-line maintenance […]

(UroToday.com) Second-generation androgen receptor signaling inhibitors have improved outcomes for men with metastatic castration-resistant prostate cancer (mCRPC), however, drug resistance invariably evolves with androgen receptor overexpression, androgen receptor mutation, or androgen receptor splice variants and subsequently continued androgen receptor signaling. TAS3681 is an oral and selective androgen receptor antagonist with androgen receptor and androgen receptor-splice variant […]

(UroToday.com) Advances in imaging have dramatically reshaped prostate cancer diagnosis, staging, and treatment. While multiparametric MRI (mpMRI) of the prostate has dramatically changed prostate cancer diagnosis, molecularly-targeted imaging has reshaped disease staging and detection of recurrent disease. Conventional imaging approaches using including computed tomography (CT) and bone scan have relatively limited sensitivity to detect disease recurrence […]

(UroToday.com) The disease natural history of patients with biochemical recurrence following radical prostatectomy is varied – while some men will have an indolent course without treatment, others progress quickly in spite of aggressive therapy. Further, treatments are not without consequence in terms of cost, inconvenience, and morbidity. Thus, better understanding disease aggressivity to target treatment intensification […]